FIELD: chemistry.
SUBSTANCE: invention relates to organic chemistry and specifically to a heterocyclic compound of the formula given below or a pharmaceutically acceptable salt or N-oxide thereof, where W, X, Y, Z, -L3P-, -R3N, R4-R8 have values given in the claim. Invention also relates to a pharmaceutical composition based on a compound of said structure and a method for production thereof, a method of inhibiting TNKS1 function or a Wnt signal, using the compound of said structure and a method of treating a proliferative disease.
EFFECT: technical result is obtaining novel heterocyclic compounds having inhibitory activity on TNKS1 function or Wnt signal.
35 cl, 36 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ALKYL SULPHONAMIDE QUINOLINES WITH AFFINITY TO NK-3 RECEPTORS | 2006 |
|
RU2421447C2 |
| DERIVATIVES OF BENZIMIDAZOL, COMPOSITIONS CONTAINING THEM, OBTAINING AND APPLICATION | 2004 |
|
RU2346938C2 |
| NOVEL PHENYLPYRAZINONES AS KINASE INHIBITORS | 2009 |
|
RU2507202C2 |
| NOVEL PHOSPHATE COMPOUNDS, SYNTHESIS METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | 2014 |
|
RU2617682C2 |
| CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND USE THEREOF IN TREATING PSYCHOTIC DISORDERS | 2011 |
|
RU2586974C2 |
| DERIVATIVES OF TETRAHYDROISOQUINOLINE, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF, METHOD FOR INHIBITION OF SYNAPTIC UPTAKE OF DOPAMINE AND TREATMENT METHOD | 2000 |
|
RU2293728C2 |
| ISOINDOLINONE INHIBITORS OF MDM2-P53 INTERACTION WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2794333C1 |
| BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | 2020 |
|
RU2811612C2 |
| 5-(PYRIDINE-2-YLAMINO)-PYRASIN-2-CARBONITRILE COMPOUNDS AND THEIR THERAPEUTIC APPLICATION | 2012 |
|
RU2641693C2 |
| COMPOUND AS WNT SIGNAL INHIBITOR, ITS COMPOSITIONS AND APPLICATION | 2012 |
|
RU2627712C2 |
